

Ceramides: A new player in the inflammation–insulin resistance paradigm?

J. M. R. Gill · N. Sattar

Received: 17 August 2009 / Accepted: 10 September 2009 / Published online: 3 October 2009
© Springer-Verlag 2009

Keywords Ceramides · IL-6 · Inflammation · Insulin resistance · TNF- α

Ceramides are a family of lipid molecules comprising sphingosine bound to a fatty acid. They form an integral part of cell membranes and, according to cosmetics manufacturers, their inclusion in hair and skin care products can help you to maintain a ‘youthful glow’. In addition to their simple structural role, ceramides also act as signalling molecules with multiple effects and, of interest to the diabetes field, a potential role for ceramides in the pathogenesis of insulin resistance has recently emerged. Increased concentrations of ceramides have been reported in skeletal muscle of obese, insulin-resistant vs lean, insulin-sensitive men [1], and strong correlations have been observed between muscle ceramide concentrations and insulin sensitivity across a wide cross-section of insulin sensitivity values [2, 3]. However, this finding is not unequivocal with another study reporting no systematic differences in skeletal muscle ceramide concentrations among four groups of men—endurance trained, lean but

untrained, obese and type 2 diabetic—although a weak correlation between ceramide concentration and insulin resistance was observed [4]. Ceramides may provide a key link between lipid oversupply, inflammation and insulin resistance, as a major determinant of ceramide synthesis is the availability of long-chain saturated fatty acids [5] and, in addition, a number of inflammatory cytokines, particularly TNF- α and IL-1, have been implicated in the regulation of ceramide production [5, 6]. In vitro studies indicate that ceramides inhibit insulin signalling in muscle cells, by decreasing insulin-stimulated activation of Akt/protein kinase B [5, 7] and by facilitating inflammatory signalling pathways known to impair insulin signalling [5, 6]. Furthermore, studies in human muscle cells [8] and rodents [9] indicate that blocking ceramide synthesis can prevent the development of insulin resistance. Thus, there is accumulating evidence that ceramides in skeletal muscle may be causally implicated in the pathogenesis of insulin resistance.

In this issue of *Diabetologia*, de Mello and colleagues [10] report a strong correlation between total plasma ceramide (measured by liquid chromatography–mass spectrometry) and serum IL-6 concentrations in a cross-sectional study of 33 patients with cardiovascular disease. A modest, borderline significant correlation ($r=0.33$, $p=0.06$) between plasma ceramide levels and HOMA-estimated insulin resistance was also observed. Ceramide concentrations explained almost 35% of the variance in circulating IL-6 levels, and this relationship was independent of serum TNF- α levels and HOMA-IR in multivariate analysis. Somewhat surprisingly, a significant correlation between plasma ceramide and serum TNF- α concentrations was not observed, although this may be a consequence of low statistical power to detect a relation-

J. M. R. Gill (✉)
Integrative and Systems Biology,
Faculty of Biomedical and Life Sciences, University of Glasgow,
West Medical Building,
Glasgow G12 8QQ, UK
e-mail: j.gill@bio.gla.ac.uk

N. Sattar (✉)
BHF Glasgow Cardiovascular Research Centre,
University of Glasgow,
126 University Place,
Glasgow G12 8TA, UK
e-mail: nsattar@clinmed.gla.ac.uk

ship owing to the relatively small sample size and the relatively high co-efficient of variation of the TNF- α assay. The authors suggest that their findings may indicate a role for ceramides in the induction of inflammation associated with the insulin resistance that is often evident in patients with CHD, although of course whether inflammation is causally related to type 2 diabetes (or, indeed, CHD) remains to be fully established.

Nevertheless, these findings are in broad agreement with a report published earlier this year by Haus and co-workers, who reported strong correlations between plasma concentrations of ceramide sub-species and both clamp-derived insulin sensitivity and plasma TNF- α concentrations in adults with and without type 2 diabetes [11]. The investigators did not measure IL-6, and so it is not known whether a relationship between circulating IL-6 and ceramides was evident, but, two studies, in different populations, have now demonstrated relationships between circulating ceramides, inflammation and insulin resistance.

These findings raise a number of important issues and questions. First, the study by de Mello et al. was cross-sectional in nature, so it is not possible to determine the direction of causality in the association between circulating IL-6 and ceramide concentrations. As inflammatory factors influence ceramide production, and ceramides themselves induce inflammation, either direction of effect is potentially plausible. In this respect, it would be of interest to determine whether individuals with autoimmune conditions have raised plasma ceramide levels and, in particular, whether such levels are influenced by TNF- α - and IL-6-blocking therapies. Similarly, it would be interesting to establish whether novel anti-inflammatory agents (e.g. anakinra, an IL-1 receptor antagonist [12]), which has been demonstrated to improve glucose control in diabetes, induce parallel decreases in plasma ceramide concentrations.

Second, the biological relevance of plasma ceramides is unknown. Are they directly implicated in the pathogenesis of insulin resistance, possibly via interactions with circulating immune cells, or do they simply serve as a marker of tissue ceramide concentrations, which themselves play a direct role in pathogenesis? The relationship between plasma and tissue ceramide concentrations in humans is not currently known. Similarly, little is known about potential links between dietary and lifestyle factors and plasma ceramide concentrations. Further studies to evaluate these issues are needed to put the interesting, but preliminary, findings from the present study into a broader context. Of course, should plasma ceramide concentrations adequately reflect tissue levels at key sites, this could accelerate studies examining their potential pathophysiological relevance to diabetes and related conditions.

In addition, the importance of plasma ceramides in terms of clinical endpoints is not known. Prospective studies are needed to ascertain whether elevated plasma ceramide concentrations predict type 2 diabetes, coronary heart disease or mortality. Such data are required to evaluate whether plasma ceramides could conceivably be used as an effective biomarker to predict risk or evaluate disease severity. However, caution is advised here for two reasons: (1) the methodology used for the determination of plasma ceramide concentrations is complex, and is likely to be costly; thus, in its present form it is unlikely to be feasible for routine clinical practice; (2) a useful biomarker must add predictive power over and above factors currently measured routinely [13], and as yet few, if any, novel biomarkers have demonstrated a consistent ability to enhance risk prediction for either CVD or diabetes beyond established predictors. Indeed, even common markers of inflammation (e.g. C-reactive protein), which are predictive of diabetes per se, do not enhance risk prediction for diabetes beyond simple clinical predictors (i.e. fasting glucose, triacylglycerol, HDL-cholesterol, blood pressure, BMI and family history) [14]. Thus, the benchmark for any new biomarker is set high.

In summary, the study of de Mello and colleagues [10], particularly when taken together with the earlier study by Haus et al. [11] provides exciting preliminary clinical data on the emerging topic of ceramides, inflammation and insulin resistance. Nevertheless, considerable further work, as outlined above, is needed to determine whether these recent findings offer new fruitful avenues in the investigation of diabetes pathogenesis.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

References

1. Adams JM, Pratipanawatr T, Berria R et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. *Diabetes* 53:25–31
2. Straczkowski M, Kowalska I, Baranowski M et al (2007) Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. *Diabetologia* 50:2366–2373
3. Straczkowski M, Kowalska I, Nikolajuk A et al (2004) Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. *Diabetes* 53:1215–1221
4. Skovbro M, Baranowski M, Skov-Jensen C et al (2008) Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. *Diabetologia* 51:1253–1260
5. Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. *Prog Lipid Res* 45:42–72
6. Holland WL, Summers SA (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. *Endocr Rev* 29:381–402

7. Straczkowski M, Kowalska I (2008) The role of skeletal muscle sphingolipids in the development of insulin resistance. *Rev Diabet Stud* 5:13–24
8. Pickersgill L, Litherland GJ, Greenberg AS, Walker M, Yeaman SJ (2007) Key role for ceramides in mediating insulin resistance in human muscle cells. *J Biol Chem* 282:12583–12589
9. Holland WL, Brozinick JT, Wang LP et al (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. *Cell Metab* 5:167–179
10. de Mello VD, Lankinen M, Schwab U et al (2010) Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. *Diabetologia*. doi:10.1007/s00125-009-1482-9
11. Haus JM, Kashyap SR, Kasumov T et al (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. *Diabetes* 58:337–343
12. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med* 356:1517–1526
13. Sattar N, Wannamethee SG, Forouhi NG (2008) Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? *Diabetologia* 51:926–940
14. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. *Arch Intern Med* 167:1068–1074